Notably, ABCA1 can also act as a tumour suppressor, promoting cell death and limiting AKT (protein kinase B) signalling via regulating the cholesterol content of the plasma membrane; missense mutations in ABCA1 are associated with enhanced proliferative potential in patients with chronic myelomonocytic leukaemia [38]. Here, AKT1 is linked to neoplasm.